Pharma BD Deal Intelligence

Astellas Pharma Inc. / Ocata Therapeutics, Inc.

2015 · Acquisition/Merger · $379M · Complete

Announcement Sentiment

Strongly positive

Astellas acquired Ocata Therapeutics (formerly Advanced Cell Technology) for $8.50/share or approximately $379M cash, establishing presence in ophthalmology and regenerative medicine via hESC-derived RPE cell therapies for Stargardt disease and dry AMD. Closed February 2016. Borderline value but strategically notable for cell therapy pivot.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Neutral

Pipeline outcome

Mixed

Assessment window: 10yr post-close.

Key facts

Announced Nov 09, 2015
Closed Feb 12, 2016
Deal value $379M
Deal type Acquisition/Merger
Therapeutic area Stargardt's macular dystrophy; dry age-related macular degeneration (AMD)
Indications Stargardt's macular dystrophy; dry age-related macular degeneration (AMD)
Key assets Retinal pigment epithelium (RPE) cell therapies (MA09-hRPE for Stargardt disease and dry AMD)
Mechanism Human embryonic stem cell-derived retinal pigment epithelium cell therapy

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals